Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Radcliffe Department of Medicine (RDM) is today (25 March 2013) hosting its Inaugural Symposium. RDM, which is part of the University of Oxford’s Medical Sciences Division, brings together about 500 staff from several research areas.

Radcliffe Department of Medicine logoThe symposium showcased the breadth of research conducted within RDM and gave researchers from across the department the opportunity to hear about their colleagues work and share ideas. In an effort to increase internal collaborations, RDM has developed an innovative funding scheme in which researchers collaborating across the department will be eligible to apply for additional funding. 

The Radcliffe Department of Medicine was formed in 2012 through an amalgamation of the Departmentof Cardiovascular Medicine, the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), the majority of research groups from the MRC Weatherall Institute of Molecular Medicine (WIMM), the Nuffield Department of Clinical Laboratory Sciences, the Oxford Acute Vascular Imaging Centre (AVIC) and the academic groups in Geratology and Stroke who were formerly members of the Nuffield Department of Medicine,  Experimental Medicine Division. These latter groups, together with a new programme in Experimental Therapeutics and the new Centre for the Advancement of Sustainable Medical Innovation (CASMI), will now constitute the Investigative Medicine Division (IMD) of RDM.

Head of Department, Professor Hugh Watkins commented: “The motivation for forming the RDM was to bring groups together that could add value to one another and I think the breadth and quality of research presented today shows just how great the potential is."

Links: 

Radcliffe Department of Medicine

Medical Sciences Division

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.